BC Week In Review | Jan 4, 2019
Clinical News

Sunovion's SEP-363856 meets in Phase II for schizophrenia

Sunovion Pharmaceuticals Inc. and partner PsychoGenics Inc. (Paramus, N.J.) said SEP-363856 met the primary endpoint in the Phase II SEP361-201 trial to treat hospitalized patients with acute exacerbations of schizophrenia. On the primary endpoint, SEP-363856...
BC Week In Review | Dec 13, 2016
Clinical News

SEP-363856: Ph II SEP361-201 started

Sumitomo Dainippon’s Sunovion Pharmaceuticals Inc. subsidiary began the double-blind, placebo-controlled, international Phase II SEP361-201 trial to evaluate 50 and 75 mg oral SEP-363856 once daily for 4 weeks in about 240 patients. Patients who complete...
BC Week In Review | Dec 13, 2016
Clinical News

SEP-363856: Ph II SEP361-203 started

Sumitomo Dainippon’s Sunovion Pharmaceuticals Inc. subsidiary began the double-blind, placebo-controlled, U.S. Phase II SEP361-203 trial to evaluate 25, 50 and 75 mg SEP-363856 once daily for 6 weeks in about 36 patients ages ≥55. The...
BC Extra | Jun 29, 2016
Financial News

Intensity raises $10M in series A

Intensity Therapeutics Inc. (Westport, Conn.) said it raised $10 million in an oversubscribed series A financing from Batterson Venture Capital, VCapital, FastForward Innovations, SalvaRx Group, Declan Doogan and Jim Mellon, plus other undisclosed investors including...
BC Week In Review | Feb 8, 2016
Company News

UCSD, PsychoGenics deal

The university granted PsychoGenics a license to a mouse model expressing human amyloid precursor protein (APP) with the K670N/M671L and V717I mutations under the control of a murine- thymus cell antigen 1 theta ( Thy1 ;...
BC Week In Review | Jan 4, 2016
Clinical News

Eltoprazine: Clinical trial data

A double-blind trial in 25 evaluable elderly AD patients with dementia who are aggressive showed that oral eltoprazine reduced SDAS total score to 16.9 points at day 29 from 25.1 points at baseline in severely...
BC Week In Review | Oct 12, 2015
Company News

PsychoGenics, Sumitomo Dainippon deal

Sumitomo Dainippon’s Sunovion Pharmaceuticals Inc. subsidiary and PsychoGenics extended for four years an August 2007 deal to develop treatments for CNS disorders. The partners have advanced one compound into clinical testing under the deal. The...
BC Week In Review | Oct 12, 2015
Clinical News

Eltoprazine: Phase IIb halted

Amarantus halted enrollment in a double-blind, placebo-controlled, 4-way crossover, international Phase IIb trial of oral eltoprazine in about 60 patients due to an “internal prioritization.” The company expects to restart enrollment next year. Amarantus has...
BC Week In Review | Sep 28, 2015
Company News

UCSD, PsychoGenics deal

The university’s school of medicine granted PsychoGenics worldwide rights to an alpha synuclein (SNCA) transgenic mouse model to research multiple system atrophy (MSA). The Line 1 model overexpresses human wild-type SNCA under control of the...
BC Week In Review | Jun 22, 2015
Clinical News

Eltoprazine: Phase IIb started

Amarantus began a double-blind, placebo-controlled, 4-way crossover, international Phase IIb trial to evaluate 2.5, 5 and 7.5 mg oral eltoprazine twice daily for 3 weeks in about 60 patients. Amarantus has exclusive, worldwide rights, excluding...
Items per page:
1 - 10 of 47
BC Week In Review | Jan 4, 2019
Clinical News

Sunovion's SEP-363856 meets in Phase II for schizophrenia

Sunovion Pharmaceuticals Inc. and partner PsychoGenics Inc. (Paramus, N.J.) said SEP-363856 met the primary endpoint in the Phase II SEP361-201 trial to treat hospitalized patients with acute exacerbations of schizophrenia. On the primary endpoint, SEP-363856...
BC Week In Review | Dec 13, 2016
Clinical News

SEP-363856: Ph II SEP361-201 started

Sumitomo Dainippon’s Sunovion Pharmaceuticals Inc. subsidiary began the double-blind, placebo-controlled, international Phase II SEP361-201 trial to evaluate 50 and 75 mg oral SEP-363856 once daily for 4 weeks in about 240 patients. Patients who complete...
BC Week In Review | Dec 13, 2016
Clinical News

SEP-363856: Ph II SEP361-203 started

Sumitomo Dainippon’s Sunovion Pharmaceuticals Inc. subsidiary began the double-blind, placebo-controlled, U.S. Phase II SEP361-203 trial to evaluate 25, 50 and 75 mg SEP-363856 once daily for 6 weeks in about 36 patients ages ≥55. The...
BC Extra | Jun 29, 2016
Financial News

Intensity raises $10M in series A

Intensity Therapeutics Inc. (Westport, Conn.) said it raised $10 million in an oversubscribed series A financing from Batterson Venture Capital, VCapital, FastForward Innovations, SalvaRx Group, Declan Doogan and Jim Mellon, plus other undisclosed investors including...
BC Week In Review | Feb 8, 2016
Company News

UCSD, PsychoGenics deal

The university granted PsychoGenics a license to a mouse model expressing human amyloid precursor protein (APP) with the K670N/M671L and V717I mutations under the control of a murine- thymus cell antigen 1 theta ( Thy1 ;...
BC Week In Review | Jan 4, 2016
Clinical News

Eltoprazine: Clinical trial data

A double-blind trial in 25 evaluable elderly AD patients with dementia who are aggressive showed that oral eltoprazine reduced SDAS total score to 16.9 points at day 29 from 25.1 points at baseline in severely...
BC Week In Review | Oct 12, 2015
Company News

PsychoGenics, Sumitomo Dainippon deal

Sumitomo Dainippon’s Sunovion Pharmaceuticals Inc. subsidiary and PsychoGenics extended for four years an August 2007 deal to develop treatments for CNS disorders. The partners have advanced one compound into clinical testing under the deal. The...
BC Week In Review | Oct 12, 2015
Clinical News

Eltoprazine: Phase IIb halted

Amarantus halted enrollment in a double-blind, placebo-controlled, 4-way crossover, international Phase IIb trial of oral eltoprazine in about 60 patients due to an “internal prioritization.” The company expects to restart enrollment next year. Amarantus has...
BC Week In Review | Sep 28, 2015
Company News

UCSD, PsychoGenics deal

The university’s school of medicine granted PsychoGenics worldwide rights to an alpha synuclein (SNCA) transgenic mouse model to research multiple system atrophy (MSA). The Line 1 model overexpresses human wild-type SNCA under control of the...
BC Week In Review | Jun 22, 2015
Clinical News

Eltoprazine: Phase IIb started

Amarantus began a double-blind, placebo-controlled, 4-way crossover, international Phase IIb trial to evaluate 2.5, 5 and 7.5 mg oral eltoprazine twice daily for 3 weeks in about 60 patients. Amarantus has exclusive, worldwide rights, excluding...
Items per page:
1 - 10 of 47